Health & Fitness
Health and Fitness
Health and Fitness
Wed, January 14, 2009
Tue, January 13, 2009
Invitrogen Launches Xenogeneic-Free Media for Human Embryonic Stem Cell Culture
CARLSBAD, Calif.--([ BUSINESS WIRE ])--Invitrogen, a division of Life Technologies Corporation (NASDAQ:LIFE), announced today that it has launched KNOCKOUT™ SR XenoFree Media for use in the culture of human embryonic stem cells (hESCs).
Until now, most of the research carried out on hESCs has used mouse-derived feeder cells and culture media containing components derived from bovine sources. Ideally, hESCs research and its translation to therapy would be performed without the use of components from other species, which prevents the contamination of hESC lines with non-human proteins that can raise regulatory questions as stem cell research moves into clinical applications.
"In order to avoid introducing contaminating proteins into human embryonic stem cells, scientists have been working for years to develop a reliable media without foreign proteins," said Joydeep Goswami, Vice President of Primary and Stem Cell Systems at Life Technologies. "KNOCKOUT™ SR XenoFree Media economically achieves this goal and will give researchers a more regulatory-friendly media in which to advance potentially ground-breaking stem cell therapies towards the clinic. This product is yet another example of how our research allows scientists to better advance the important work being done in regenerative medicine."
KNOCKOUT™ SR XenoFree Media is based on KNOCKOUT™ SR, the gold standard reagent for the maintenance of undifferentiated hESCs while maintaining pluripotency, with more than 200 publications documenting its use. All components are either human-derived or synthetic, resulting in a completely xenogeneic-free formulation.
More information about KNOCKOUT™ SR XenoFree Media can be found at [ www.invitrogen.com/stemcell/ksrxf ].
Life Technologies, through its Invitrogen division, is the premier provider of products and services for advancing the field of regenerative medicine. Its efforts are focused on supplying researchers with the most comprehensive suite of products for advancing cell therapy efforts, including the industry's premier portfolio of tools and reagents for stem cell research. The company also focuses on creating unique primary and stem cell models for better and more efficient drug screening. More information about Invitrogen's offerings in regenerative medicine can be found at [ www.invitrogen.com/stemcell ].
About Life Technologies
Life Technologies (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies has historical sales of approximately $3.5 billion, employs 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of over 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website [ www.lifetechnologies.com ].
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
